

PDT: Therapies On the Cutting Edge

Clinical trials are under way to develop innovative and effective treatment modalities for wet age-related macular degeneration.

SINCE THE U.S. FOOD AND DRUG Administration approved photodynamic therapy with verteporfin for the treatment of predominantly classic subfoveal choroidal neovascularization and other ocular pathologies secondary to age-related macular degeneration, researchers have been studying expanded uses of the technology alone and in concert with other vascular drug treatments. A new era in the treatment of CNV due to AMD has quickly emerged.

In clinical trials, researchers are experimenting with various laser-light intensities and delayed light-application techniques to establish new treatment modalities for minimally classic and occult with no classic CNV—two forms of AMD that have no FDA-approved therapies in the United States. Other studies are concluding for the first time that verteporfin (Visudyne, Novartis AG) is safe and effective for long-term use, and retrospective subgroup analyses are demonstrating that lesion size plays a critical role in positive visual-acuity outcomes regardless of lesion composition.

Following is an update on the cutting-edge research in verteporfin therapy that ophthalmologists hope will create new therapies to serve a wider range of patients.

Predominantly Classic CNV

Researchers from the third-year, open-label extension of the Treatment of AMD with Photodynamic Therapy (TAP) investigation have found that vision remained relatively stable for five years in most verteporfin-treated patients with predominantly classic CNV, and that fewer retreatments were needed to maintain vision, according to Peter K. Kaiser, MD, a vitreoretinal surgeon at Cole Eye Institute in Cleveland.

"The extension study showed that vision stabilized in most patients with predominantly classic CNV lesions who received verteporfin and that the treatment remained safe throughout the 60 months. So we now know that verteporfin therapy is safe and effective in

patients for at least five years," says Dr. Kaiser.

The clinical trial included 124 of the original 159 verteporfin-treated patients (78 percent) who had completed two years of the TAP study and who were considered good candidates to benefit further from the therapy. Since not all patients in the TAP investigation participated in the extension, researchers express caution when interpreting these results.


In other research, investigators launched the Verteporfin Early Retreatment (VER) trial, an ongoing Phase III study of 323 patients, to determine whether verteporfin retreatments six weeks after initial therapy versus the standard three months is more beneficial.

Following the first verteporfin treatment at baseline, all patients are receiving retreatments at three months and six months. Half are randomly

Judith Springer Riddle
Associate Editor



Left: Predominantly classic subfoveal choroidal neovascularization prior to PDT. Right: A fluorescein angiogram nine months after a third session of PDT.



selected, however, to receive verteporfin six weeks and four and a half months after the initial infusion.

The study is based on the rationale that 80 percent of vision loss in verteporfin-treated patients who lose visual acuity occurs in the first six months after treatment when abnormal blood vessels rejuvenate and advance the disease. "So if we can treat the abnormal blood vessels when they first come back to life, we should be able to limit vision loss in patients," says Louis A. Lobes, Jr., MD, partner of Retina Vitreous Consultants and clinical associate professor at the University of Pittsburgh Medical School. "The other theory is if we treat the lesions more frequently, we can limit the size of the final active lesion and, therefore, decrease the amount of visual damage." One-year results of the 24-month trial are expected early in 2004.

Occult with No Classic CNV

The need for an FDA-approved treatment for occult CNV in the United States has spurred researchers to begin the Visudyne in Occult (VIO) trial—a 24-month, multicenter study that's analyzing a subset of patients with occult lesions who participated in the Visudyne in Photodynamic Therapy (VIP) study. The latter showed positive visual-acuity outcomes in verteporfin-treated patients with occult CNV.

The VIO trial will include 360 patients, age 50 and older, who will be enrolled at 30 centers in the U.S. and 11 sites in Canada, according to researcher Kevin J. Blinder, MD, a vitreoretinal specialist at Barnes Retina Institute, and assistant professor of ophthalmology at Washington University School of Medicine in St. Louis.

"The VIO trial is essentially identical to the VIP study, but it incorporates what we've learned from the VIP trial, namely that smaller lesions respond


better to Visudyne treatment," says Dr. Kaiser, the VIO-study chairman. "The FDA liked the results [of the VIP trial], but it wants more proof that patients with small occult lesions respond better to treatment."

Results from a retrospective subgroup analysis of the VIP trial, which followed the disease course of occult CNV, showed that patients with occult lesions less than or equal to 4 MPS (Macular Photocoagulation Study) disc areas and baseline visual-acuity scores worse than 20/50 benefited most from verteporfin therapy and immediate treatment.

"Due to these results, a lot of physicians are not waiting for the results of the VIO trial but are using PDT to

fornia Retina Consultants in Santa Barbara, Calif., and co-director of the California Retina Research Foundation, physicians should watch and wait. The reason: Patients with larger lesions and higher levels of visual acuity are less likely to benefit from verteporfin treatment—as evidenced in the VIP trial. So they should be monitored for conversion or for vision loss, at which time they may be considered for possible verteporfin therapy.

"It's unclear why these patients didn't benefit from verteporfin treatment," says Dr. Pieramici. "Perhaps, they represent a subgroup of patients who have foveal photoreceptors that are relatively resilient to the effects of subfoveal CNV. Or, they may have



Left: Fluorescein angiogram of an occult with no classic CNV lesion prior to PDT therapy. Right: The same occult lesion six months after a single session of verteporfin.

treat occult lesions off label," says Dr. Kaiser. "Instead of sitting around and watching patients lose vision, treatment is instituted."

Based on the VIP subgroup analysis, researchers raised an important question: Should ophthalmologists promptly treat patients with occult with no classic lesions greater than 4 MPS disc areas and who have visual acuity scores of 20/50 or better as well or take the watch-and-wait approach until they convert to a predominantly classic composition that may benefit from treatment?

According to Dante J. Pieramici, MD, a retinal specialist with the Cali-

what some have termed 'a survivor lesion' that manifests more benign pathophysiology."

In the Verteporfin with Altered (Delayed) Light in Occult (VALIO) study, researchers delayed non-thermal laser-light application for 30 minutes and for the standard 15 minutes after initiating a verteporfin infusion in patients with occult lesions. Sixty patients (median age 78) were equally randomized to the 15- or 30-minute treatment arm.

Six-month data show that patients in the 30-minute group lost 1.3 lines of vision compared with those in the 15-minute treatment arm who lost two to

three lines, says principal investigator Jason S. Slakter, MD, clinical professor of ophthalmology at New York University School of Medicine, and surgeon director at Manhattan Eye, Ear and Throat Hospital in New York City.

One-year results of the trial are expected late this year.

Researchers are encouraged by these results in that there's potential "for manipulation of the [standard] treatment regimen to provide better visual outcomes," says Dr. Slakter.

The theory behind delaying light application for an additional 15 minutes after administering a verteporfin infusion comes from previous clinical trials that have shown higher closure rates in occult lesions as a result. "Because of certain flow characteristics inherent in occult vessels, verteporfin builds up within [diseased] blood vessels while at the same time decreases in the surrounding normal tissue [as time progresses]. The end result is more drug in the target tissue and less drug in the normal tissue. So, theoretically, you get a more selective treatment," says Dr. Slakter.

Minimally Classic CNV

Retrospective subgroup analyses of the TAP investigation and VIP trial, led by Susan B. Bressler, MD, professor of ophthalmology at Johns Hopkins University School of Medicine in Baltimore, suggest that lesion size is an important predictor of treatment benefit for minimally classic and occult lesions.

Based on her data, Dr. Bressler suggests treating minimally classic and occult with no classic CNV when lesions are equal to or less than 4 MPS disc areas and to continue treating predominantly classic blood vessels regardless of size. Further, she recommends that physicians treat smaller lesions regardless of blood-vessel composition and consider undertaking larger lesions if a poor natural history exists



Left: A fluorescein angiogram of a minimally classic CNV lesion. Baseline visual acuity is 20/200. **Right:** The classic component of the neovascular membrane is much smaller three months following one verteporfin treatment, although the occult membrane remains visible. Visual acuity is 20/60.

Will Verteporfin Soon Have Competition?

Verteporfin is the only weapon in the ophthalmologist's armamentarium that's been approved by the U.S. Food and Drug Administration to treat wet age-related macular degeneration. But will it continue to be the only photosensitizing drug on the market?

Miravant Medical Technologies in Santa Barbara, Calif., the maker of the lipophilic photosensitizer drug Photopoint SnET2, plans to file its first New Drug Application for marketing approval. The decision came after two randomized Phase III clinical trials showed positive visual-acuity results in a significant number of patients treated with the drug.

Visual stability in the SnET2-treated patients with predominantly classic and minimally classic lesions was statistically significant versus those who received placebo. The studies also showed that the drug is safe and well-tolerated and may be used for a broader population of wet AMD patients than verteporfin (Visudyne, Novartis AG), which is only approved for predominantly classic choroidal neovascularization in the United States.

Like Visudyne, SnET2 is a light-activated drug designed to target abnormal blood vessels beneath the macula.

"There's a big question mark as to whether SnET2 will be FDA-approved," says Carl D. Regillo, MD, professor of ophthalmology at Wills Eye Hospital, Thomas Jefferson University in Philadelphia. "It seems to be showing that it stabilizes vision. The safety profile after two years of follow up seems to be favorable. But the big question is how well does it work? It's a matter of finding out how useful it will be in treating the various forms of AMD."

One photosensitizing drug that was recently in the clinical-trial pipeline but has since been pulled is Lu-Tex/Optrin (lutetium texaphyrin, Pharmacyclics, Sunnyvale, Calif.). "The preliminary rates of closure and the side effects such as paresthesia seen at higher doses suggested that [the drug] wasn't going to be as useful a vessel-closure agent as verteporfin," says Mark S. Blumenkranz, MD, chairman of the department of ophthalmology at Stanford Medical Center in Stanford, Calif.

VIGAMOX™

(moxifloxacin hydrochloride ophthalmic solution) 0.5% as base

DESCRIPTION: VIGAMOX™ (moxifloxacin HCl ophthalmic solution) 0.5% is a sterile ophthalmic solution. It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.

Clinical Studies: In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, VIGAMOX™ solution produced clinical cures on day 5-6 in 66% to 69% of patients treated for bacterial conjunctivitis. Microbiological success rates for the eradication of the baseline pathogens ranged from 84% to 94%. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.

INDICATIONS AND USAGE: VIGAMOX™ solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Aerobic Gram-positive microorganisms:

Corynebacterium species,* *Micrococcus luteus**, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus warneri**, *Streptococcus pneumoniae*, *Streptococcus viridans* group

Aerobic Gram-negative microorganisms:

*Acinetobacter lwoffii**, *Haemophilus influenzae*, *Haemophilus parainfluenzae**

Other microorganisms:

Chlamydia trachomatis

*Efficacy for this organism was studied in fewer than 10 infections.

CONTRAINDICATIONS: VIGAMOX™ (moxifloxacin HCl ophthalmic solution) is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.

WARNINGS:

NOT FOR INJECTION.

VIGAMOX™ solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.

PRECAUTIONS:

General: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers or other source.

Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.

Drug Interactions: Drug-drug interaction studies have not been conducted with VIGAMOX™ solution. *In vitro* studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose for a 50 kg person, on a mg/kg basis). Moxifloxacin was not mutagenic in four bacterial strains used in the Ames *Salmonella* reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity *in vivo* in a micronucleus test or a dominant lethal test in mice.

Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 21,700 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.

Pregnancy: Teratogenic Effects.

Pregnancy Category C: Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of teratogenicity when pregnant cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.

Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX™ solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when VIGAMOX™ solution is administered to a nursing mother.

Pediatric Use: The safety and effectiveness of VIGAMOX™ solution in infants below 1 year of age have not been established.

There is no evidence that the ophthalmic administration of VIGAMOX™ has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.

Geriatric Use: No overall differences in safety and effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS:

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients.

Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

Rx Only

Manufactured by

Alcon Laboratories, Inc.

Fort Worth, Texas 76134 USA

Licensed from Bayer AG to Alcon, Inc.

U.S. PAT. NO. 4,990,517; 5,607,942; 5,849,752

© 2003 Alcon, Inc.

REVIEW COVER STORY

Combining the Best of Both Worlds

Verteporfin may slow the progression of vision loss in most patients with age-related macular degeneration, but it doesn't stop disease recurrence or restore lost vision permanently. So researchers are conducting clinical trials combining verteporfin (Visudyne, Novartis AG) therapy with angiogenesis inhibitors, drugs that prevent blood-vessel growth, such as rhuFab V2 (ranibizumab, Genentech) and triamcinolone acetonide (Kenalog) in hopes of curing the disease.

"Antiangiogenesis drugs used with verteporfin offer the best theoretical opportunity for optimal visual outcomes," says Louis A. Lobes, Jr., MD, partner of Retina Vitreous Consultants and clinical associate professor at the University of Pittsburgh Medical School. "We know that patients on verteporfin alone continue to lose vision, so we need to add something to it. Verteporfin will be the foundation, and the antiangiogenesis drugs will block the VEGF stimulus that may result in better visual outcomes."

Here are the angiogenesis inhibitors currently being combined with verteporfin therapy in clinical trials.

RhuFab V2

RhuFab V2, or Lucentis, is an anti-VEGF (vascular endothelial growth factor) antibody fragment that's administered by intravitreal injection. It binds and inhibits VEGF, a protein that plays a critical role in ocular angiogenesis, thus blocking new blood-vessel growth.

Improvements in visual-acuity scores in previous Phase I/II trials after using rhuFab V2 have prompted researchers to introduce multiple Phase III studies this year.

A dose-comparison, open-label clinical trial, called the Focus study, is under way to determine if injections of rhuFab V2 into the eye in combination with verteporfin is a safe, effective and tolerable treatment for patients with predominantly classic choroidal neovascularization secondary to AMD. Researchers will compare the combination therapy to a verteporfin-only regimen.



Two other trials are also in progress: The Marina study is recruiting 720 patients with minimally classic and occult CNV to compare rhuFab V2 injections alone to placebo. The Anchor trial is pitting rhuFab V2 alone against verteporfin therapy in 400 patients with predominantly classic lesions, says Ted McCluskey, MD, PhD, medical director and senior clinical scientist at Genentech, Inc., in San Francisco.

Triamcinolone Acetonide

Previous studies have shown that the corticosteroid triamcinolone acetonide improves visual acuity in patients with CNV when combined with verteporfin. The studies included

a limited number of patients, but the positive visual-acuity outcomes and lack of fluorescein leakage have prompted a team of New York researchers, led by Richard F. Spaide, MD, partner of Vitreous-Retina-Macula Consultants of New York, to begin a multicenter, randomized phase II trial later this year that will again assess the effectiveness of Kenalog intravitreal injections following verteporfin treatment.

During the three-year study, patients will receive either verteporfin followed by a sham injection or verteporfin combined with a Kenalog injection, says Jason S. Slakter, MD, clinical professor of ophthalmology at New York University School of Medicine, and surgeon director of Manhattan Eye, Ear and Throat Hospital in New York City. Researchers will assess visual acuity and CNV closure rates to determine the number of retreatments needed for optimal visual outcomes.



Left: Leakage in an occult lesion following two prior PDT sessions. Right: Cessation of leakage three months following PDT combined with Kenalog injections.

Anecortave Acetate

Called an angiostatic steroid, anecortave acetate (Alcon) inhibits blood-vessel growth and is delivered by juxtasclear injection. Presently, no studies are under way combining the drug with verteporfin. But a recently completed six-month trial compared anecortave acetate and verteporfin therapy to PDT alone.

In the placebo-controlled, double-masked trial, 136 patients were randomized to receive a single 15-mg, 30-mg, or placebo injection of anecortave acetate one week following verteporfin therapy. Visual acuity stabilized in 78 percent of patients who received the combination treatment compared to just 67 percent of those treated with PDT alone. Recruitment for a Phase III study is under way to compare anecortave acetate alone to verteporfin for the treatment of wet AMD.

Macugen

Eyetech recently launched a phase II/III, randomized, multicenter trial to establish the safety and efficacy of intravitreal injections of the anti-VEGF agent Macugen (pegaptanib sodium) in patients with CNV due to wet AMD.

The two-year comparative study will determine if Macugen alone or combined with verteporfin will stabilize or improve vision. Approximately, 1,200 patients have been enrolled in 117 medical centers around the world. Researchers will measure visual-acuity outcomes as their primary endpoint.

(i.e., predominantly classic vessels).

These recent findings astounded one physician who, like many others, couldn't figure out why verteporfin therapy wasn't working for minimally classic CNV. "[That study] is an amazing story," says Dr. Lobes, "because there was no clear understanding why predominantly classic and occult lesions were responding but minimally classic CNV was not. It was a counter-intuitive result you might say."

Lawrence J. Singerman, MD, FACS, president of Retina Associates of Cleveland, and clinical professor of ophthalmology at Case Western Reserve University, says "Lesion size is the most important determinant in visual outcome, and we finally have the data that show that clearly. Small lesions benefit from verteporfin no matter what the lesion composition, and if we can get that understood and sold to the FDA it would simplify things, bring clarity to doctors on how and when to treat their patients, and it would also allow more people to benefit from PDT."

Promising new data from the ongoing Visudyne in Minimally Classic (VIM) trial bolster the finding that small lesion size is a prime factor in successfully treating minimally classic lesions.

Participants in the Phase II, 24-month trial have minimally classic lesions equal to or less than 6 MPS disc areas—a significant difference from the lesion sizes of patients in the TAP investigation that ranged in size up to 9 MPS disc areas, which may explain why verteporfin therapy showed no benefit for these patients, says Philip J. Rosenfeld, MD, PhD, associate professor of ophthalmology at Bascom Palmer Eye Institute in Miami.

In the study, researchers are looking at the potential benefit of verteporfin therapy using a reduced or standard fluence (laser-light intensity) rate com-

pared to placebo in 117 patients with minimally classic CNV. Twelve-month preliminary findings show that 39 patients in the standard fluence group lost a mean of eight letters on the Early Diabetic Retinopathy Study visual-acuity chart compared with 38 people who lost a mean of five letters in the reduced fluence treatment arm. Patients receiving placebo in both fluence groups lost a mean of 14 letters.

"For the first time, we've been able to show a treatment benefit for minimally classic CNV," says Dr. Rosenfeld. "Patients treated with verteporfin have a reduced risk of vision loss and an increased chance of stable or improved vision."

The VIM study also showed that verteporfin-treated patients with minimally classic lesions were less likely to convert to predominantly classic CNV.


Yet, according to a retrospective subgroup analysis of patients with minimally classic CNV who were given placebo in the TAP investigation, researchers found that 40 percent of minimally classic lesions converted to a predominantly classic component over a 24-month period, with most of the conversions occurring in the first three months. Additionally, visual acuity and lesion size at the time of conversion in many patients were within a range where verteporfin therapy may reduce the risk of further vision loss.

Based on this data, investigators suggest that physicians monitor patients with minimally classic CNV closely within the first year of diagnosis if they're not receiving verteporfin therapy. That way, if they convert to predominantly classic CNV, they may be eligible for treatment.

Facing the Future

With the wealth of research under way and plans to conduct additional studies in the future, researchers are optimistic and particularly enthusiastic about the possibility of establishing new and effective therapies for their patients. "This is a very exciting time for us in retina," says Dr. Blinder. "We're dealing with a disease that we don't fully understand yet and have not had effective treatment modalities for in the past. But I think the next few years will show us a multitude of treatments for our patients."

Dr. Kaiser agrees. "I think all the research is very exciting for ophthalmologists. There are a lot of clinical studies going on and each one seems to be better than the one before."

The race to develop effective treatments for AMD, says Dr. Rosenfeld, is analogous to a sporting event. "We're all looking for that edge that will give our patients a performance advantage. Any gains or progress we make will come from making modifications to the PDT protocol. We're only looking at incremental gains at this point, but those are important." 



ALLERGIC EYES STOP HERE

DESCRIPTION

PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H₁-receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes.

INDICATIONS AND USAGE

PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

CONTRAINDICATIONS

PATANOL is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of PATANOL.

WARNINGS

PATANOL is for topical use only and not for injection or oral use.

PRECAUTIONS

Information for Patients: To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Patients should be advised not to wear a contact lens if their eye is red. PATANOL® should not be used to treat contact lens related irritation. The preservative in PATANOL, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling PATANOL before they insert their contact lenses.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µL drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an *in vitro* bacterial reverse mutation (Ames) test, an *in vitro* mammalian chromosome aberration assay or an *in vivo* mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human use level.

Pregnancy: Pregnancy Category C. Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Nursing Mothers: Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATANOL is administered to a nursing mother.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

ADVERSE REACTIONS

Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: Asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

DOSAGE AND ADMINISTRATION

The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

HOW SUPPLIED

PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is supplied as follows:

- 5 mL in plastic DROP-TAINER® dispenser.
- 5 mL NDC 0065-0271-05.

Rx Only

U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805.

Revised: April 2000

References:

1. Data on file, Alcon Laboratories, Inc.
2. Scott-Levin's *Physician Drug & Diagnosis Audit* (PDDA) from Verispan, L.L.C., January-September 2002.
3. Scott-Levin's *Source Prescription Audit* (SPA) from Verispan, L.L.C., March 1997-October 2002.

Alcon®

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134
www.alconlabs.com